Isaac J. Bright, MD
Co-Founder and Chief Executive Officer
Dr. Bright is an entrepreneurial physician with a robust track-record building shareholder value and delivering transactional success for more than a decade. Following completion of his MD at Stanford University School of Medicine, Isaac served as Financial Analyst at CIBC World Markets in 2004. Dr. Bright was an esteemed Howard E. Mitchell Fellow, earning his MBA at The Wharton School between 2004-2006. Isaac Joined the Medtronic Corporate Development team in 2006, and quickly progressed to more complete deal leadership responsibilities, becoming Director of Business Development for Medtronic Neuromodulation in 2008. Capitalizing on his broad, blue-chip deal experiences, Dr. Bright joined the leadership team of QuantaLife, Inc. in 2009 and drove the Company’s financing and strategic transaction initiatives through the successful trade-sale to Bio-Rad Laboratories in 2011. Dr. Bright spent more than 4 years serving as the only American Partner for Merieux Developement, with €220M under management. Isaac served briefly as Vice President of Corporate Development at Synthetic Biologics, Inc. in 2016, prior to supporting Muse bio’s $23M Series B Preferred Equity financing in early 2017. Dr. Bright joined HealthTell as Chief Business Officer in April 2017, and drove the Company’s merger with PatientsLikeMe and iCarbonX, concomitant with the $10M Series A spin-out of RubrYc Therapeutics Inc., in March 2018.
Matthew P. Greving, Ph.D.
Co-Founder and VP, Technology
Dr. Greving has a passion for innovation and an awarded track record in commercialization of technologies that advance pharma and biotech discovery. Dr. Greving founded his first company 20 years ago to develop new software algorithms that made the large data stores housed on legacy mainframe systems accessible to modern internet-based systems. Many of the core algorithms he developed continue to serve as an architectural framework for today’s big data, highly-parallel transaction processing systems. In 2010 Dr. Greving completed his Ph.D. in Biochemistry. His thesis research produced some of the key innovations and intellectual property behind HealthTell’s Immunosignature technology for diagnostics. Dr. Greving completed his post-doctoral research at The Scripps Research Institute (TSRI) with a focus on metabolomics and high-throughput mass spectrometry. After his post-doctoral work, Dr. Greving founded Nextval, where he developed a new array-based mass spectrometry laboratory and software platform that set a new standard in high-throughput enzyme screening. Notably, his developments at Nextval resulted in receiving two prestigious innovation awards. First, The Society of Lab Automation and Screening (SLAS) 2012 “Innovation of the Year Award” for his high-throughput drug toxicity screening platform. Second, R&D Magazine’s “2013 R&D 100 Oscar of Innovation” for his high-throughput enzyme screening platform. After successfully exiting Nextval, Dr. Greving joined HealthTell as a Principal Scientist to continue development on the Immunosignature technology. In addition, he initiated the R&D to apply HealthTell’s high-density library platform towards significantly advancing therapeutic discovery, which ultimately resulted in the spin-out of RubrYc.
Mohan Srinivasan, Ph.D.
Co-Founder and VP, Discovery
Dr. Srinivasan, a biophysicist by training, has spent almost 25 years in the field of protein and antibody engineering. After his graduate studies in computational biology to investigate nucleic acids, at the University of Madras, Dr. Srinivasan continued his research career at the National Cancer Institute, NIH, Bethesda working on antibody structure-function and engineering, in the laboratory of Dr. Sandra Smith-Gill. His research here yielded important insights into the molecular mechanisms that govern the nature of cross-reactivity and specificity of antibodies. He continued this work at the laboratory of Prof Richard Willson at the Department of Chemical Engineering, University of Houston, which further substantiated this seminal observation. His deep research background in antibody structure-function helped launch his industrial career in the year 2001, when he joined the premier antibody biotech company Medarex, as part of their antibody discovery program. He was instrumental in ground-up creation of their first comprehensive protein science laboratory and establishing research for systematic characterization, engineering and optimization of their therapeutic antibody molecules. As a member of the discovery teams, at Medarex, and later after the acquisition of Medarex by Bristol-Myers Squibb in 2009, Dr. Srinivasan co-invented, engineered and optimized several highly successful therapeutic antibodies including the landmark nivolumab. Dr. Srinivasan has to his credit over 45 patents in field of antibody discovery, engineering and optimization and 25 publications. He has also been credited with several awards for his performances at Medarex and BMS, which spanned almost 16 years. In 2017, he joined the immunomics leader HealthTell, as Senior Director of Therapeutic Antibody R&D, where he was responsible for initiation of their internal therapeutic antibody discovery efforts, that has been instrumental in the spin-out of RubrYc Therapeutics. His expertise spans all fields associated with antibody discovery, engineering and early development for FIH studies. He has been an invited speaker and chair on numerous international conferences on antibody discovery. Dr. Srinivasan obtained his undergraduate and graduate degrees in Physics and Biophysics from the University of Madras. He regularly volunteers at local Bay Area soup kitchens and community activities.
David Passmore, MBA
Head of Commercial Operations
Mr. Passmore is a seasoned Biotechnology professional having over 20 years of technical and operations experience with discovery-stage organizations developing first-in-class biotherapeutics. After completion of a B.S. degree in chemistry, Mr. Passmore initiated his scientific career in the mid-1990’s with Anergen, a biotechnology company that pioneered immuno-therapies against autoreactive T-Cells. Mr. Passmore later joined Dynavax Technologies to work on the early development of CpG immuno-stimulants as vaccine adjuvants. In 2001 Mr. Passmore signed on with immuno-oncology leader Medarex where he established, and built over time, a state-of-the-art analytical lab for characterization of therapeutic antibodies to support discovery operations. During his tenure at Medarex, Mr. Passmore was an integral part of the team that discovered ipilimumab (Yervoy®), nivolumab (Opdivo®), and an anti-PD-L1 therapeutic antibody. It was at this time that Mr. Passmore completed an Executive MBA program through Pepperdine University. Mr. Passmore went to Bristol-Myers Squibb in 2009 as part of the BMS acquisition of Medarex. At BMS Mr. Passmore led a team of scientists that identified clinical candidates for multiple programs in immuno-oncology and targeted cancer therapies. Additionally, Mr. Passmore spearheaded the technical evaluation and development of novel therapeutic modalities such as antibody-drug conjugates, tumor-activated antibodies, and Fc-enhanced mAbs. Mr. Passmore’s work at BMS and Medarex was incorporated in numerous scientific publications and patent applications; over the course of his career, Mr. Passmore has authored many articles in peer-reviewed journals and has been awarded 11 US patents for his inventions in the field of therapeutic antibodies. Drawing on his deep industry experience and business training, Mr. Passmore founded a consulting practice in 2017 to provide technical and commercial services to biotechnology companies; including at immunomics leader HealthTell, where he was instrumental in the spin-out of RubrYc Therapeutics in March 2018. Mr. Passmore currently heads up the commercial team at RubrYc and is responsible for the company’s marketing strategy, communications, and business development activities.
Bill W. Colston, PhD
Executive Chairman, Board of Directors
Dr. Colston started his career at Lawrence Livermore National Laboratory (LLNL), where he helped build one of the largest civilian biodefense programs in the country. He left LLNL in 2008 to found a new company, QuantaLife Inc., where he and his team developed a highly accurate genetic analysis system called Droplet Digital PCR. QuantaLife grew exponentially during his tenure as CEO and was sold to BioRad in 2011. Shortly after his departure from BioRad, Dr. Colston helped found a new life sciences company, HealthTell Inc. This exciting new venture has created a powerful new test for profiling an individual’s immune status and has formed partnerships to enable a new generation of diagnostics and therapies. A prolific scientific writer and inventor, Dr. Colston sits on the Board of Directors for HealthTell, Rheonix, and Purigen Biosystems.